Prognostic differences between type Ⅰ and type Ⅱ renal papillary cell carcinoma
10.3969/j.issn.1009-8291.2023.03.011
- VernacularTitle:Ⅰ型和Ⅱ型肾乳头状细胞癌患者预后差异分析
- Author:
Wenjie YANG
1
;
Jie DONG
1
;
Lin MA
1
;
Zhigang JI
1
;
Weifeng XU
1
Author Information
1. Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
- Publication Type:Journal Article
- Keywords:
renal cancer;
papillary renal cell carcinoma;
histologic subtypes;
clinical characteristics;
prognosis
- From:
Journal of Modern Urology
2023;28(3):227-231
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To analyze the clinical characteristics and prognostic differences between type Ⅰ and type Ⅱ papillary renal cell carcinoma (PRCC), and identify the prognosis-related independent predictors. 【Methods】 A total of 143 PRCC patients treated during Jan.2012 and Dec.2019 were involved, including 91 type Ⅰ patients and 52 type Ⅱ patients. The prognostic factors were analyzed with univariate and multivariate Cox regression analysis. The differences in cancer-specific survival (CSS) between the two groups were analyzed with Kaplan-Meier method and log-rank test. 【Results】 The patients’ age was 53.41±13.50 years. After a mean follow-up of 63.27±26.20 months, 14 patients died, and the overall CSS was 90.2%. The prognosis of type Ⅰ patients was better than type Ⅱ patients (94.5% vs. 82.7%, P=0.020). Cox regression suggested that PRCC subtype and stage were significantly associated with prognosis. There was no difference in prognosis between type Ⅰ and type Ⅱ patients in T1/T2 subgroup (P>0.05). However, in T3/T4 subgroup, type Ⅰ patients had a significant better prognosis than type Ⅱ patients (P=0.023), while the above trends were not observed in G1/G2 and G3/G4 subgroups (P>0.05). 【Conclusion】 PRCC subtype and stage are independent prognostic predictors. The impact of PRCC subtype on prognosis is mainly manifested in the subgroup of patients with T3 or higher stage.
